LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET. Webcast details will be accessible from the “Investors & Media” section ...

VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) ("SHARC Energy" or the “Company”) is pleased to announce it has filed financial results for the three and nine months ended September 30, 2025. All figures are in Canadian Dollars and in accordance with IFRS unless otherwise stated. Third Quarter and Year to Date (YTD) Financial Highlights: Revenue for the nine months ended September 30, 2025 (“YTD 2025”) is $2.69 million (M ...

HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) announced today a monthly distribution of $0.08 per share for December 2025. This distribution is payable to common stockholders on December 31, 2025 (as outlined in the table below). The Company declares and pays distributions on a monthly basis. Payment of future distributions is subject to the approval of the Company’s Board of Directors, as well as meeting the covenants on the Company’s debt agreem ...

TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Stack Capital Group Inc. (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A; TSX:STCK.WT.B) announced today that the Toronto Stock Exchange (the “TSX”) has accepted a notice filed by Stack Capital of its intention to make a normal course issuer bid (the “NCIB”) with respect to its outstanding common shares. Stack Capital management believes its share price is undervalued compared to its recently announced Book Value per Share of $14.26. The notice provides ...

KUALA LUMPUR, Malaysia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company, today announced an ambitious projection of more than 500% revenue growth for 2026. This anticipated surge is supported by several key operational milestones achieved across its fintech and digital asset ecosystem. These strategic advancements, including the development of the OXI Wallet, the UNIRWA real-world asset (RWA) tokenization ...

Core Viewpoint - Jeffs' Brands Ltd has entered into a non-binding Memorandum of Understanding (MOU) with Scanary Ltd to distribute AI-driven electromagnetic imaging security systems, marking a strategic entry into the global homeland-security sector [1][5]. Group 1: MOU Details - The MOU grants Jeffs' Brands Holdings the right to market and distribute Scanary's AI-radar screening systems, which can scan up to 25,000 people per hour without stopping them [2]. - The system provides real-time threat detection in under two seconds, utilizing 3D imaging and AI technology, and is designed for high-demand environments such as airports and stadiums [3]. - Jeffs' Brands Holdings will make a one-time payment of $1,000,000 to Scanary, payable in five installments, and will receive a demo system and technical support [4]. Group 2: Market Potential - The security scanning equipment market was valued at over USD 11.4 billion in 2022 and is expected to grow at a CAGR of over 7% from 2023 to 2032 [4]. - Jeffs' Brands Holdings will have exclusive distribution rights in Canada, Germany, and the UAE for an initial 24-month period, with the possibility of renewal based on sales performance [8]. Group 3: Corporate Rebranding - The MOU includes plans for a corporate rebranding of Jeffs' Brands Holdings to "KeepZone Technologies Inc." to align with its new focus on security technology [5].

Study findings to be featured in a poster spotlight presentationHOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Anto ...

Core Insights - Zorevunersen shows potential as a disease-modifying therapy for Dravet syndrome, supported by four years of clinical data and EEG assessments [1][2][3] Company Overview - Biogen Inc. is a leading biotechnology company focused on innovative science to develop new medicines [7] - Stoke Therapeutics specializes in RNA medicine aimed at restoring protein expression, with zorevunersen as its first investigational product [9] Product Information - Zorevunersen is an investigational antisense oligonucleotide targeting the underlying cause of Dravet syndrome by increasing NaV1.1 protein production [5] - The drug has received orphan drug designation and Breakthrough Therapy Designation from the FDA for Dravet syndrome [5] Clinical Studies - The ongoing EMPEROR Phase 3 study evaluates zorevunersen's efficacy in children with Dravet syndrome, focusing on seizure frequency and cognitive improvements [6] - Data from the Phase 1/2a and ongoing open-label extension studies will be presented at the 2025 American Epilepsy Society Annual Meeting [2][3] Disease Context - Dravet syndrome is characterized by severe seizures and cognitive impairments, with a significant portion of patients not achieving adequate seizure control with existing treatments [4] - Approximately 38,000 individuals are estimated to be living with Dravet syndrome in the U.S., UK, EU-4, and Japan [4]

Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMIS on track to leverage new plasma pTau insights with planned Q2 2026 interim readout Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in ne ...

VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pulse Oil Corp. (“Pulse” or the "Company”) (TSXV: PUL) is pleased to announce that Pulse has entered into amending agreements to the two loan Facility Agreements (the “Facility Agreements”) with two arms-length parties to the Company (the “Lenders”) announced in the Company’s press release of June 5, 2025. Pursuant to the amending agreements, each of the Lenders has agreed to increase their respective loan to the Company (collectively, the “Loan ...